Editing Diabetic retinopathy (section)

===Mild or moderate NPDR===
For those with mild to moderate non-proliferative diabetic retinopathy, the American Academy of Ophthalmology recommends only more frequent retinal exams—every six to twelve months—as these people are at an increased risk of developing proliferative retinopathy or macular edema.{{sfn|Flaxel|Adelman|Bailey|Fawzi|2020|loc="Mild to moderate NPDR without macular edema"}} Injection of [[anti-VEGF]] drugs or steroids can reduce diabetic retinopathy progression in around half of eyes treated; however, whether this results in improved vision long term is not yet known.{{sfn|Brownlee|Aiello|Sun|Cooper|2020|loc="Treatment of nonproliferative diabetic retinopathy”}} The lipid-lowering drug [[fenofibrate]] also reduces progression of disease in people with mild to moderate disease.<ref>{{cite journal | vauthors = Ngah NF, Muhamad NA, Abdul Aziz RA, Mohamed SO, Ahmad Tarmizi NA, Adnan A, Asnir ZZ, Hussein Z, Siew HF, Mohamed M, Lodz NA, Valayatham V | title = Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice | journal = International Journal of Ophthalmology | volume = 15 | issue = 12 | pages = 2001–2008 | date = 2022-12-18 | pmid = 36536974 | pmc = 9729076 | doi = 10.18240/ijo.2022.12.16 }}</ref><ref>{{Cite web |title=Trial: Fenofibrate Slows Diabetic Retinopathy Progression |url=https://www.medscape.com/viewarticle/trial-fenofibrate-slows-diabetic-retinopathy-progression-2024a1000bm8 |access-date=2024-07-29 |website=Medscape |language=en}}</ref>